Federation des caisses Desjardins du Quebec Increases Stake in Danaher Corporation $DHR

Key Points

• The Federation des caisses Desjardins du Quebec increased its stake in Danaher Corporation by 19.2% in the first quarter, bringing its total holding to approximately $22.49 million.
• Several large investors, including Vanguard and Invesco, have also recently raised their positions in Danaher, which now has 79.05% of its shares held by institutional investors and hedge funds.
• Danaher reported earnings of $1.80 per share for the last quarter, exceeding analysts' expectations, and set its FY 2025 guidance at 7.700-7.800 EPS.

Federation des caisses Desjardins du Quebec raised its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 19.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,727 shares of the conglomerate's stock after acquiring an additional 17,712 shares during the period. Federation des caisses Desjardins du Quebec's holdings in Danaher were worth $22,494,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of DHR. Bank Pictet & Cie Europe AG grew its position in shares of Danaher by 22.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after buying an additional 35,730 shares in the last quarter. Aptus Capital Advisors LLC lifted its position in shares of Danaher by 8.6% in the fourth quarter. Aptus Capital Advisors LLC now owns 7,078 shares of the conglomerate's stock valued at $1,626,000 after acquiring an additional 562 shares in the last quarter. Benjamin Edwards Inc. increased its position in shares of Danaher by 13.5% during the 4th quarter. Benjamin Edwards Inc. now owns 15,322 shares of the conglomerate's stock worth $3,517,000 after purchasing an additional 1,826 shares during the last quarter. Cary Street Partners Financial LLC acquired a new position in Danaher during the 4th quarter worth $1,754,000. Finally, Bridgefront Capital LLC acquired a new stake in shares of Danaher in the 4th quarter valued at about $698,000. Institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

Shares of DHR stock traded up $1.29 during midday trading on Friday, hitting $200.32. 2,837,584 shares of the company were exchanged, compared to its average volume of 2,859,442. The firm has a market capitalization of $143.44 billion, a P/E ratio of 42.62, a PEG ratio of 2.79 and a beta of 0.75. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm's 50 day moving average price is $201.93 and its two-hundred day moving average price is $199.37. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's revenue was up 3.4% on a year-over-year basis. During the same period last year, the company earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Deutsche Bank Aktiengesellschaft lowered their price objective on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Evercore ISI reduced their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Finally, Wells Fargo & Company cut their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 11.10% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.